Table 1.
Clinical characteristics of patients in each period of dialysis initiation.
| All | 1979–2009 | 2010–2014 | 2015–2020 | p Value | |
|---|---|---|---|---|---|
| Number of patients, n | 291 | 119 | 71 | 101 | / |
| Age at initiation of dialysis | |||||
| Mean ± SD | 65.6 ± 14.4 | 59.1 ± 13.9 | 70.4 ± 11.4 | 69.8 ± 14.2 | <0.001 * |
| Range (years) | 21–95 | 21–90 | 43–93 | 33–95 | |
| Follow-up period (years) | |||||
| Mean ± SD | 8.1 ± 7.8 | 14.3 ± 8.5 | 6.3 ± 2.5 | 2.1 ± 1.5 | <0.001 * |
| Range (years) | 0.1–38.3 | 0.3–38.3 | 0.2–10.3 | 0.1–5.1 | |
| Male, n (%) | 187 (64.3%) | 68 (57.1%) | 46 (64.8%) | 73 (72.3%) | 0.065 |
| Underlying diseases, n (%) | |||||
| Hypertension | 283 (97.3%) | 118 (99.2%) | 69 (97.2%) | 96 (95.0%) | 0.178 |
| Diabetes | 177 (60.8%) | 65 (54.6%) | 52 (73.2%) | 60 (59.4%) | 0.037 * |
| Dyslipidemia | 114 (39.2%) | 34 (28.6%) | 28 (39.4%) | 52 (51.5%) | 0.002 * |
| Ischemic heart diseases | 132 (45.4%) | 63 (52.9%) | 38 (53.5%) | 31 (30.7%) | 0.001 * |
| Arteriosclerosis obliterans | 92 (31.6%) | 42 (35.3%) | 28 (39.4%) | 22 (21.8%) | 0.026 * |
| Atrial fibrillation | 31 (10.7%) | 47 (14.3%) | 6 (8.5%) | 8 (7.9%) | 0.252 |
| Smoking, n (%) | 110 (37.8%) | 32 (26.9%) | 26 (36.6%) | 52 (51.5%) | 0.001 * |
| Alcohol, n (%) | 51 (17.5%) | 16 (13.5%) | 12 (16.9%) | 23 (22.8%) | 0.191 |
| Online HDF, n (%) | 69 (23.1%) | 29 (24.4%) | 18 (25.4%) | 22 (21.8%) | 0.842 |
| Antiplatelet therapy, n (%) | 148 (50.9%) | 62 (52.1%) | 40 (56.3%) | 46 (45.5%) | 0.356 |
| Anticoagulant therapy, n (%) | 35 (12.0%) | 21 (17.7%) | 7 (9.9%) | 7 (6.9%) | 0.042 * |
| Primary renal diagnosis of the patients, n (%) |
|||||
| Diabetic nephropathy | 116 (39.9%) | 40 (33.6%) | 33 (46.5%) | 43 (42.6%) | 0.001 * |
| Nephrosclerosis | 75 (25.8%) | 22 (18.5%) | 26 (36.6%) | 27 (26.7%) | |
| Glomerulonephritis | 44 (15.1%) | 29 (24.4%) | 6 (8.5%) | 9 (8.9%) | |
| Polycystic kidney disease | 11 (3.8%) | 5 (4.2%) | 2 (2.8%) | 4 (4.0%) | |
| Others | 45 (15.5%) | 23 (19.3%) | 4 (5.6%) | 18 (17.8%) | |
| Laboratory parameters | |||||
| CRP (mg/dL) | |||||
| Mean ± SD | 0.97 ± 3.27 | 0.92 ± 2.93 | 0.59 ± 1.42 | 1.29 ± 4.38 | 0.001 * |
| Range (mg/dL) | 0.00–30.98 | 0.00–26.1 | 0.00–10.1 | 0.00–30.98 | |
| PTH (pg/mL) | |||||
| Mean ± SD | 183 ± 177 | 191 ± 179 | 187 ± 227 | 172 ± 126 | 0.965 |
| Range (pg/mL) | 5–1842 | 6–1260 | 5–1842 | 7–724 | |
| Kt/V | |||||
| Mean ± SD | 1.27 ± 0.33 | 1.30 ± 0.33 | 1.20 ± 0.31 | 1.29 ± 0.33 | 0.061 |
| Range | 0.48–2.21 | 0.48–2.21 | 0.59–1.82 | 0.51–2.16 | |
| URR (%) | |||||
| Mean ± SD | 62.9 ± 10.6 | 63.5 ± 11.3 | 59.6 ± 11.1 | 64.4 ± 8.8 | 0.011 * |
| Range (%) | 26.7–93.9 | 26.7–93.9 | 32.6–77.8 | 36.1–82.5 |
n, number; SD, standard deviation; HDF, hemodialysis filtration; CRP, C-reactive protein; PTH, parathyroid hormone; Kt/V, K dialyzer clearance of urea, t dialysis time, V volume of distribution of urea; URR, urea reduction ratio. * Values of p < 0.05 are considered statistically significant.